Barr Laboratories Inc has received approval from the U.S. Food and Drug Administration (FDA) for Pyridostigmine Bromide Tablets USP, 60 mg, the generic equivalent of ICN Pharmaceutical, Inc.'s Mestinon. The Company anticipates launching its product by the end of October 2003.
Pyridostigmine Bromide is an orally active cholinesterase inhibitor useful in the treatment of myasthenia gravis.
Barr's Pyridostigmine Bromide Tablets will compete in a market that had total combined annual sales of approximately $19.4 million, based on IMS sales data for the twelve months ending August 2003.